Zinbryta risks outweigh benefits, European report

Multiple sclerosis treatment Zinbryta was withdrawn in March and now a review by the European Medicines Agency has found its risks outweigh its benefits. The review confirms the drug’s association with the risk of developing severe and potentially fatal immune reactions in the brain, liver and other organs. It was carried out by to the …

Advertisement

MS treatment Zinbryta (daclizumab) withdrawn worldwide amid safety concerns

Disease modifying therapy daclizumab (Zinbryta) has been withdrawn from sale worldwide. Its manufacturers took the decision after reports that a number of people taking the treatment developed serious inflammatory brain disorders. That’s how the news was announced on the MS Society’s website. In the UK, the treatment will no longer be available via the country’s …

Zinbryta use restricted in Europe after a death and four serious liver injuries

The European Medicines Agency (EMA) has restricted the use of multiple sclerosis drug Zinbryta. The agency took action after a patient died from liver injury (fulminant liver failure). The patient was in an ongoing observational study. Four cases of serious liver injury have also been reported. We are all likely to experience some side effect …

After Long Wait, Zinbryta Gains Approval in Areas of the UK

News that daclizumab, brand name Zinbryta, has been given the go-ahead to be available through the U.K.’s National Health Service (NHS) for treating relapsing MS, at least in part of the country, is good news. But why has the decision taken so long? Possibly, because the first decision, last September, was ‘no.’ The latest decision by …

Just two weeks to fight for MS treatment

Anyone wishing to take issue with the draft recommendation to not make daclizumab1 (Zinbryta) be made available as a treatment on the NHS in England and Wales has just 15 days to do so. Comments must be received by Friday October 21. So, if you want a change of heart, don't delay. The time to …

New MS drug approved in USA and Europe

A new disease modifying treatment is being considered for use in the UK following it being approved in the USA and Europe. Already approved by America’s Food and Drug Administration (FDA), daclizumab, known as Zinbryta, has now been given the nod by the European Medicines Agency (EMA). The agency has recommended that the drug be …